Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
University of Michigan Health Systems
mi
from
Ann Arbor, MI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Clinical Research Institute of Michigan,
mi
from
Chesterfield, MI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Clinical Research Institute of Michigan,
mi
from
Chesterfield, MI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Center for Digestive Health
mi
from
Troy, MI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Center for Digestive Health
mi
from
Troy, MI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Charlotte Gastroenterology and Hepatology
mi
from
Charlotte, NC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Charlotte Gastroenterology and Hepatology
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Charlotte Radiology
mi
from
Charlotte, NC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Charlotte Radiology
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Charlotte Radiology
mi
from
Huntersville, NC
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Charlotte Radiology
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Cleveland Clinic
mi
from
Cleveland, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Investigational Drug Services - University Hospitals Case Medical Center
mi
from
Cleveland, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Investigational Drug Services - University Hospitals Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
University Hospitals of Cleveland
mi
from
Cleveland, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Dayton Gastroenterology, Inc.
mi
from
Dayton, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Dayton Gastroenterology, Inc.
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Great Lakes Gastroenterology
mi
from
Mentor, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Great Lakes Gastroenterology
mi
from
Mentor, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
The Endoscopy Center of Lake County
mi
from
Mentor, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
The Endoscopy Center of Lake County
mi
from
Mentor, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Great Lakes Gastroenterology
mi
from
Willoughby, OH
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Great Lakes Gastroenterology
mi
from
Willoughby, OH
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Regional Gastroenterology Associates of Lancaster, LTD
mi
from
Lancaster, PA
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Regional Gastroenterology Associates of Lancaster, LTD
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
DM Clinical Research
mi
from
Houston, TX
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
DM Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Ut Health Science Center
mi
from
Houston, TX
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Ut Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Digestive Health Specialists of Tyler
mi
from
Tyler, TX
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Digestive Health Specialists of Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
University of Utah
mi
from
Salt Lake City, UT
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Cardiology Consultants (ECG Site Only)
mi
from
Norfolk, VA
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Cardiology Consultants (ECG Site Only)
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
MRI & CT Diagnostics
mi
from
Virginia Beach, VA
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
MRI & CT Diagnostics
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Medical Diagnostic Imaging (MDI) X-ray and MRI only
mi
from
Milwaukee, WI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Medical Diagnostic Imaging (MDI) X-ray and MRI only
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Center for Digestive Health
mi
from
Milwaukee, WI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Center for Digestive Health
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Wisconsin Center for Advanced Research - GI Associates, LLC
mi
from
Milwaukee, WI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Wisconsin Center for Advanced Research - GI Associates, LLC
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
Allegiance Research Specialists
mi
from
Wauwatosa, WI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
Allegiance Research Specialists
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  2/13/2015
GI Associates
mi
from
Wauwatosa, WI
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 2/13/2015
GI Associates
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Santa Barbara, CA
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Chicago, IL
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Local Institution
mi
from
Reno, NV
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Local Institution
mi
from
Reno, NV
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Greenville, NC
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Greenville, NC
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Garden Grove, CA
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Roseville, CA
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Miami, FL
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Topeka, KA
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
West Yarmouth, MA
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
West Yarmouth, MA
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Great Neck, NY
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Charlotte, NC
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Raleigh, NC
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Cincinnati, OH
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Medford, OR
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Simpsonville, SC
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Memphis, TN
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Houston, TX
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  4/10/2015
GSK Investigational Site
mi
from
Calgary,
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 4/10/2015
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
Status: Enrolling
Updated:  4/17/2015
Stanford Hospital and Clinics
mi
from
Stanford, CA
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
Status: Enrolling
Updated: 4/17/2015
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials